TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2088520

Group type: EXPERIMENTAL
Intervention: Single session post-partum counselling regarding contraception and reproductive behaviour for HIV positive women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group of uninfected women matched for pregnancy outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single session post-partum counselling for HIV positive women
Number of subjects: 0
Study: 6102797

Group type: EXPERIMENTAL
Intervention: Placebo or low dosages of antipsychotics (PLD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: High conventional dosages of antipsychotics (HCD)
Number of subjects: 61
Study: 31959220

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality intervention during HSG
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Routine care plus immersive VR intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immersive VR intervention
Number of subjects: 200
Study: 30979397

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 5354

Group type: COMPARATOR
Intervention: Other bDMARDs
Number of subjects: 5354
Study: 27011294

Group type: EXPERIMENTAL
Intervention: 1,000 mg fish oil supplements daily containing 120 mg DHA and 180 mg EPA
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24288076

Group type: EXPERIMENTAL
Intervention: Modified quadrant method for measuring femoral tunnel positions
Number of subjects: 41
Study: 23196671

Group type: EXPERIMENTAL
Intervention: Hass avocado (68 g) with hamburger
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hamburger alone (250 g)
Number of subjects: 11
Study: 20522672

Group type: EXPERIMENTAL
Intervention: ACEi/ARBs
Number of subjects: 452

Group type: COMPARATOR
Intervention: Not treated with ACEi/ARBs
Number of subjects: 452
Study: 18608632

Group type: EXPERIMENTAL
Intervention: Screen time of 3-4 hours/day
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Screen time of more than 4 hours/day
Number of subjects: 580

Group type: COMPARATOR
Intervention: Screen time of less than 2 hours/day
Number of subjects: 580
Study: 16434753

Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural (CSE) anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural anesthesia alone
Number of subjects: 80
Study: 12547847

Group type: EXPERIMENTAL
Intervention: Acarbose (titrated up to 100 mg b.i.d.)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 11180022

Group type: EXPERIMENTAL
Intervention: Cetrorelix 1 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cetrorelix 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 36
Study: 1726004

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 to 6 mg once daily)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 to 50 mg once daily)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 362

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 362
Study: 6354408

Group type: EXPERIMENTAL
Intervention: Cefazolin (first-generation cephalosporin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Erythromycin base and metronidazole (oral)
Number of subjects: 44
Study: 31474490

Group type: EXPERIMENTAL
Intervention: Preoperative teaching by a lymphedema expert
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (standard preoperative surgical discussion and literature)
Number of subjects: 119
Study: 30288999

Group type: EXPERIMENTAL
Intervention: automated closed-loop therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: sensor-augmented pump therapy
Number of subjects: 16
Study: 26908016

Group type: EXPERIMENTAL
Intervention: Management strategies involving drug discontinuation only (37%)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Management strategies involving drug discontinuation with transfusion of red cell concentrates (38%)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Management strategies involving drug discontinuation with transfusion of plasma (23%)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Management strategies involving coagulation factor concentrates (2%)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Warfarin management
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Non-traumatic bleeding management
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Traumatic bleeding management
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: 30-day mortality rates
Number of subjects: 1034
Study: 24650828

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22885247

Group type: EXPERIMENTAL
Intervention: 2 mg THC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6 mg THC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: THC (all doses)
Number of subjects: 12
Study: 19897312

Group type: EXPERIMENTAL
Intervention: BI+Usual Care
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 44
Study: 17654228

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (mean 10 degrees C, s = 0.5) for 10 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-immersion)
Number of subjects: 20
Study: 15773823

Group type: COMPARATOR
Intervention: Nociceptin levels in headache-free migraineurs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nociceptin levels in controls
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nociceptin levels in patients during typical migraine attacks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation of nociceptin levels with frequency of attacks in migraineurs
Number of subjects: 18
Study: 11812708

Group type: EXPERIMENTAL
Intervention: Isotonic sport drinks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water only
Number of subjects: 60
Study: 10363564

Group type: EXPERIMENTAL
Intervention: Mn-SOD in carcinomas and liver metastases
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mn-SOD in adenomas
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cu/Zn-SOD in liver metastases
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cu/Zn-SOD in adenomas, carcinomas, and normal mucosa
Number of subjects: 105
Study: 7739942

Group type: EXPERIMENTAL
Intervention: Generic slow-release theophylline tablet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 14
Study: 2154070

Group type: EXPERIMENTAL
Intervention: VLCD with dietary fibre
Number of subjects: 22

Group type: COMPARATOR
Intervention: VLCD without dietary fibre
Number of subjects: 22
Study: 6342643

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (various doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 12
Study: 30586756

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 118

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 118
Study: 29356928

Group type: EXPERIMENTAL
Intervention: self‐directed, technology‐based sessions
Number of subjects: 412

Group type: COMPARATOR
Intervention: in‐person, small group sessions led by facilitators
Number of subjects: 412

Group type: COMPARATOR
Intervention: literature control with home‐mailed educational materials
Number of subjects: 412
Study: 27098817

Group type: EXPERIMENTAL
Intervention: CET as a smartphone application
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CET as group therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Aftercare as Usual
Number of subjects: 300
Study: 24677247

Group type: EXPERIMENTAL
Intervention: Late onset melancholic depression (LOD-M)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Early onset melancholic depression (EOD-M)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Age at onset (predictor)
Number of subjects: 284
Study: 23054852

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 80
Study: 20386062

Group type: EXPERIMENTAL
Intervention: Creative arts therapy (CAT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Volunteer attention (Control)
Number of subjects: 16
Study: 18714203

Group type: EXPERIMENTAL
Intervention: Massage therapy (body stroking and passive limb movements for three, 15-minute periods per day for 5 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard nursery care without massage therapy
Number of subjects: 42
Study: 16177615

Group type: EXPERIMENTAL
Intervention: Easy warm-up (EWU)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hard warm-up (HWU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 8
Study: 12529344

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 448
Study: 10408495

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 0
Study: 8911372

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine dermal patches postauricularly
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study: 1875230

Group type: EXPERIMENTAL
Intervention: Cefotetan (total dose, 20 g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clindamycin (total dose, 12 g) plus Amikacin (total dose, 5 g)
Number of subjects: 41
Study: 6897369

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide) with delays of less than 10 weeks
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC) with delays of 10-13 weeks
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC) with delays of 14-17 weeks
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (FAC) with delays of greater than or equal to 18 weeks
Number of subjects: 460
Study: 31328298

Group type: EXPERIMENTAL
Intervention: DX ICD system
Number of subjects: 150

Group type: COMPARATOR
Intervention: Single-chamber ICD cohort
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dual-chamber ICD cohort
Number of subjects: 150
Study: 29921393

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (cFNB) with 0.375% ropivacaine hydrochloride, 20 mL loading dose
Number of subjects: 46

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with fentanyl, 0.05 mg loading dose
Number of subjects: 46
Study: 27852324

Group type: EXPERIMENTAL
Intervention: Hand-hygiene intervention
Number of subjects: 775
Study: 24025033

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy combined with functional strength training
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conventional physical therapy combined with movement performance therapy
Number of subjects: 288
Study: 22595900

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy neonates
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nontreated neonates
Number of subjects: 41
Study: 19641362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 2 weeks
Number of subjects: 146
Study: 17998017

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (1000 microg Cr/d as Cr picolinate)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 15251616

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 394

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 394
Study: 12226016

Group type: EXPERIMENTAL
Intervention: Salmeterol (25 micro g, two puffs bid for 6 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (two puffs bid for 6 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Salmeterol and Placebo
Number of subjects: 27
Study: 9513753

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone (ANH)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 8122946

Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 2518874

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 792579

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide‐methylprednisolone (group A)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Methylprednisolone‐procarbazine hydrochloride (group B)
Number of subjects: 13
Study: 31548270

Group type: EXPERIMENTAL
Intervention: Overexpression of Hp0897 full-length protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of Hp0897CTD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of Hp0897NTD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hp0897CTD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hp0897 full-length protein
Number of subjects: 0
Study: 28033544

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5244
Study: 25990624

Group type: EXPERIMENTAL
Intervention: Plasma galectin-3 (gal-3) levels in HD patients with left ventricular diastolic dysfunction (LVDD)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Plasma galectin-3 (gal-3) levels in HD patients with normal diastolic function
Number of subjects: 132

Group type: COMPARATOR
Intervention: Plasma galectin-3 (gal-3) levels in healthy controls
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Correlation of plasma gal-3 levels with E/E' ratio
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Correlation of plasma gal-3 levels with left atrial volume index
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Correlation of plasma gal-3 levels with E'
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Gal-3 cut-off point for diagnosis of LVDD
Number of subjects: 132
Study: 23788809

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (HSBP) measurement
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Normal systolic blood pressure (NSBP) measurement
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure (HDBP) measurement
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Normal diastolic blood pressure (NDBP) measurement
Number of subjects: 116
Study: 21748770

Group type: COMPARATOR
Intervention: Rosiglitazone alone (4 mg twice-daily)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Rosiglitazone and metformin (4 mg rosiglitazone and 500 mg metformin twice-daily)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Rosiglitazone and losartan (4 mg rosiglitazone and 50 mg losartan once-daily)
Number of subjects: 137
Study: 19890172

Group type: EXPERIMENTAL
Intervention: Home-based educational and environmental intervention delivered by lay health educators
Number of subjects: 264
Study: 16620334

Group type: EXPERIMENTAL
Intervention: Coblation uvulopalatoplasty with tonsillectomy (CP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: KTP laser-assisted uvulopalatoplasty without tonsillectomy (LAUP)
Number of subjects: 30
Study: 14625121

Group type: EXPERIMENTAL
Intervention: Oral 17beta‐E2 + NETA for 3 months
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: CEE + MPA for 3 months
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 + MPA for 3 months
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 + MPA for 12 months
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels in HRT users
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (not receiving HRT)
Number of subjects: 241
Study: 11182960

Group type: EXPERIMENTAL
Intervention: Telephone care (three intervening telephone appointments scheduled)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 512
Study: 8626941

Group type: EXPERIMENTAL
Intervention: GUSTO trial participants
Number of subjects: 12309

Group type: EXPERIMENTAL
Intervention: LATE trial participants
Number of subjects: 12309

Group type: COMPARATOR
Intervention: Nonparticipants at GUSTO hospitals
Number of subjects: 12309

Group type: COMPARATOR
Intervention: Nonparticipants at LATE hospitals
Number of subjects: 12309
Study: 1593561

Group type: EXPERIMENTAL
Intervention: Hygroscopic cervical dilators
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Hygroscopic cervical dilators and Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 74
Study: 2934579

Group type: EXPERIMENTAL
Intervention: Combination therapy with flutamide and LHRH agonist (or orchiectomy)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Orchiectomy alone
Number of subjects: 87
Study: 31439956

Group type: EXPERIMENTAL
Intervention: Steroids (n=77)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (n=67)
Number of subjects: 144
Study: 29936668

Group type: EXPERIMENTAL
Intervention: CADence acoustic detection (AD) system
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Nuclear stress testing (objective performance criteria)
Number of subjects: 1013
Study: 27830671

Group type: EXPERIMENTAL
Intervention: Serum prolidase activity
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total oxidant status (TOS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oxidative stress index (OSI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS)
Number of subjects: 35
Study: 25352732

Group type: EXPERIMENTAL
Intervention: Four tablets at full dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Two softgels at full dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: One softgel at half-dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Zinc absorption
Number of subjects: 15
Study: 22967121

Group type: EXPERIMENTAL
Intervention: Levofloxacin/amoxicillin/esomeprazole
Number of subjects: 101

Group type: COMPARATOR
Intervention: Esomeprazole/metronidazole/bismuth salt/tetracycline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Levofloxacin-resistant strains
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Levofloxacin-susceptible strains
Number of subjects: 101
Study: 20082201

Group type: EXPERIMENTAL
Intervention: Lower blepharoplasty with periorbital fat mobilization and arcus marginalis redrape
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservatively standard fat‐resection lower blepharoplasty
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 50
Study: 18827122

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 100
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 50
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 1308
Study: 12735532

Group type: EXPERIMENTAL
Intervention: Home physiotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hospital physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hospital therapy
Number of subjects: 40
Study: 10647713

Group type: EXPERIMENTAL
Intervention: Presence of hemorrhages and microaneurysms (h/ma) temporal to the macula (photographic field 3) as severe as or more severe than ETDRS standard photograph 1 (h/ma 3 >= 3)
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Single examination for detecting PDR
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Single examination for moderate NPDR or worse
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Presence of any hard exudate within one disc diameter of the macular center
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Hard exudate of moderate or worse severity anywhere in the macular region (field 2)
Number of subjects: 3711
Study: 9575669

Group type: EXPERIMENTAL
Intervention: c‐EOAE in noise-exposed individuals
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: c‐EOAE spectrum analysis
Number of subjects: 122
Study: 8398529

Group type: EXPERIMENTAL
Intervention: Morphine and droperidol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 50
Study: 2943643

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin K 2165
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 10
Study: 29637434

Group type: EXPERIMENTAL
Intervention: Enhanced messages about safe sleep practices to prevent SIDS and suffocation
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Standard messages about safe sleep practices to reduce the risk of SIDS
Number of subjects: 1194
Study: 26547291

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg biweekly (Q2W) or 420 mg monthly (QM)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo Q2W or QM
Number of subjects: 404
Study: 24767519

Group type: EXPERIMENTAL
Intervention: Protocol-directed physical therapy (pdPT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham treatment (ST)
Number of subjects: 300
Study: 22831781

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (8 trains applied over two consecutive days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without stimulation
Number of subjects: 0
Study: 19965537

Group type: EXPERIMENTAL
Intervention: HDF
Number of subjects: 406

Group type: COMPARATOR
Intervention: HD
Number of subjects: 406
Study: 18480036

Group type: EXPERIMENTAL
Intervention: Percentage format (e.g., 12%)
Number of subjects: 16133

Group type: EXPERIMENTAL
Intervention: Frequency format (e.g., 12 in 100)
Number of subjects: 16133

Group type: COMPARATOR
Intervention: 1-in-n format (e.g., 1 in 8)
Number of subjects: 16133